Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells

Cited by papers we hold 12

• Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer · 2023
  No notice
• Exploiting innate immunity for cancer immunotherapy · 2023
  No notice
• Advances in immunotherapy for triple-negative breast cancer · 2023
  Corrected
• Leveraging NKG2D Ligands in Immuno-Oncology · 2021
  No notice
• Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy · 2020
  No notice
• NK Cell-Based Immune Checkpoint Inhibition · 2020
  No notice
• Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy · 2020
  No notice
• How to select IgG subclasses in developing anti-tumor therapeutic antibodies · 2020
  No notice
• Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer · 2020
  No notice
• Clinical development of targeted and immune based anti-cancer therapies · 2019
  No notice
• PD-1/PD-L1 Inhibitors in Cervical Cancer · 2019
  No notice
• Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.